ClinicalTrials.gg
RecruitingNCT05861895Updated Jun 26, 2026

HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors

A Phase 1 interventional study of HF158K1 / 1.4 g lipid dose and HF158K1 / 2.2 g lipid dose in Solid Tumors, Adult, sponsored by HighField Biopharmaceuticals Corporation. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by HighField Biopharmaceuticals Corporation · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

HF158K1 is an investigational liposome form of doxorubicin hydrochloride, an anthracycline topoisomerase inhibitor, encapsulated by lipid membranes containing TL01, a HER2-directed Trastuzumab Fab fragment conjugated lipid.

Read the detailed description

This study is a multi-regional, open-label, multiple-dose administration dose-escalation and dose-expansion study, including a Dose-Escalation Phase (Ia) and a Dose-Expansion Phase (Ib).

HF158K1 contains multiple copies of the targeting antibody on liposome surface. It is designed to bind and deliver the chemotherapeutic doxorubicin to tumor cells at even very low HER2 expression levels. The study recruits patients with unresectable or metastatic advanced solid tumors (HER-2 positive (IHC 3+, or IHC 2+ with ISH +) or HER-2 low expression (IHC 2+ with ISH -, or IHC 1+)) who have failed or are intolerant (disease progression, or intolerance to chemotherapy, targeted therapy, etc.) to standard treatment, or currently have no available treatment regimen.

Phase 1a(Dose escalation) will assess the safety,tolerability,pharmacokinetics of HF158K1 in participants to determine the maximum tolerated dose (MTD) of HF158K1 through the incidence of dose-limiting toxicity (DLT).

Phase 1b (Dose bridging) will be conducted in Chinese patients to bridge the safety and pharmacokinetic data between different ethnic populations.

Phase 1c(Dose expansion) will assess safety and preliminary efficacy of HF158K1 in participants with specific tumor types in selected dose groups.

02

Conditions studied

  • Solid Tumors, Adult
03

In context

Lead sponsor

HighField Biopharmaceuticals Corporation is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary to participate and sign ICF.
  2. Age ≥ 18 and ≤ 75 years.
  3. Unresectable or advanced solid tumors with expression (IHC 3+, 2+, or 1+).
  4. score 0-1.
  5. Expected survival ≥ 6 months.
  6. At least one per v1.1.
  7. Adequate organ function: ≥ 1.5×10⁹/L, LYM ≥ 1.0×10⁹/L, ≥ 90×10⁹/L, HGB ≥ 8.0 g/dL; ≤ 1.5×, INR ≤ 1.5; ≤ 1.5×ULN, /AST ≤ 2.5×ULN (≤ 5×ULN if liver metastases); ≥ 30 mL/min; ≥ 50%.
  8. Agreement to use effective .

Exclusion criteria

Exclusion Criteria:

  1. Cumulative doxorubicin dose ≥ 350 mg/m² or prior anthracycline-induced cardiotoxicity.
  2. Current use of or systemic (> 10 mg/day prednisone).
  3. Prior anti-tumor therapy \< 2 weeks (4 weeks for nitrosourea/mitomycin C).
  4. Symptomatic .
  5. Unresolved AEs from prior therapy > Grade 1.
  6. Serious cardiovascular diseases (thromboembolic events within 3 months, III-IV, ACS within 6 months, or uncontrolled hypertension).
  7. Active infection or unexplained fever > 38.5°C.
  8. , active or .
  9. Pregnant or breastfeeding.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Dose escalation: HF158K1 1.4 g lipid dose

    Participants in this dose group (1.4 g lipid dose) will receive HF158K1 on D1 of each treatment cycle (3 weeks as a treatment cycle) through intravenous infusion.

    Drug: HF158K1 / 1.4 g lipid dose

  • Experimental
    Dose escalation: HF158K1 2.2 g lipid dose

    Participants in this dose group (2.2 g lipid dose) will receive HF158K1 on D1 of each treatment cycle (3 weeks as a treatment cycle) through intravenous infusion.

    Drug: HF158K1 / 2.2 g lipid dose

  • Experimental
    Dose escalation: HF158K1 2.9 g lipid dose

    Participants in this dose group (2.9 g lipid dose) will receive HF158K1 on D1 of each treatment cycle (3 weeks as a treatment cycle) through intravenous infusion.

    Drug: HF158K1 / 2.9 g lipid dose

Interventions

  • DrugHF158K1 / 1.4 g lipid dose

    Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.

    Also known as: Infusion

  • DrugHF158K1 / 2.2 g lipid dose

    Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.

    Also known as: Infusion

  • DrugHF158K1 / 2.9 g lipid dose

    Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.

    Also known as: Infusion

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    Defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE V5.0)

    Time frame: The period of AE collection starts after the participant receives the investigational drug, until 28±3 days after the EOT/early withdrawal or before the participant starts another anti-tumor treatment (whichever occurs first).

  2. Incidence of dose-limiting toxicities(DLT)

    Observe the dose limiting toxicity, and Incidence of dose-limiting toxicities(DLT) will be assessed

    Time frame: The DLT evaluation period is from the first administration of the investigational drug to the end of the first treatment cycle, lasting for 21 days.(only Ia)

  3. Red blood cell count in whole blood sample

    Changes from baseline for Red blood cell count in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  4. White blood cell in whole blood sample

    Changes from baseline for white blood cell count in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  5. Hematocrit in whole blood sample

    Changes from baseline for Hematocrit in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  6. Neutrophil count in whole blood sample

    Changes from baseline for neutrophil count in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  7. Hemoglobin concentration in whole blood sample

    Changes from baseline for hemoglobin concentration in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  8. Percentage of lymphocytes (LYM%)

    Changes from baseline for Percentage of lymphocytes (LYM%) in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  9. Lymphocyte count

    Changes from baseline for Lymphocyte count in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  10. Percentage of neutrophils (NEU%) Percentage of neutrophils (NEU%)

    Changes from baseline for Percentage of neutrophils (NEU%) in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  11. Platelet count in whole blood sample

    Changes from baseline for Platelet count in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  12. Prothrombin time in whole blood sample

    Changes from baseline for Prothrombin time in whole blood sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  13. International normalized ratio in whole blood sample

    Changes from baseline for international standardized ratio in whole blood sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  14. Fibrinogen in whole blood sample

    Changes from baseline for Fibrinogen in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  15. Activated partial prothrombin time in whole blood sample

    Changes from baseline for activated partial thromboplastin time in whole blood sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  16. Total bilirubin concentration in whole blood sample

    Changes from baseline for total bilirubin concentration in whole blood sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  17. ALT concentration in whole blood sample

    Changes from baseline for alanine aminotransferase(ALT) concentration in whole blood sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  18. AST concentration in whole blood sample

    Changes from baseline for aspartate aminotransferase(AST) concentration in whole blood sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  19. Total protein concentration in whole blood sample

    Changes from baseline for total protein concentration in whole blood sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  20. Urea concentration in whole blood sample

    Changes from baseline for urea concentration in whole blood sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  21. Creatinine concentration in whole blood sample

    Changes from baseline for creatinine concentration in whole blood sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  22. Total cholesterol concentration in whole blood sample

    Changes from baseline for total cholesterol concentration in whole blood sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  23. Triglycerides concentration in whole blood sample

    Changes from baseline for triglycerides concentration in whole blood sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  24. HDL-C in whole blood sample

    Changes from baseline for high density lipoprotein cholesterol (HDL-C) in whole blood sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  25. LDL-C in whole blood sample

    Changes from baseline for low density lipoprotein cholesterol (LDL-C) in whole blood sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  26. Glucose in whole blood sample

    Changes from baseline for Lactic dehydrogenase in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  27. Alkaline phosphatase in whole blood sample

    Changes from baseline for Lactic dehydrogenase in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  28. Lactic dehydrogenase in whole blood sample

    Changes from baseline for Lactic dehydrogenase in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  29. Gamma-glutamyl transferase in whole blood sample

    Changes from baseline for Gamma-glutamyl transferase in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  30. Albumin in whole blood sample

    Changes from baseline for Albumin in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  31. Direct bilirubin in whole blood sample

    Changes from baseline for Direct bilirubin in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  32. Sodium in whole blood sample

    Changes from baseline for Sodium in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  33. Potassium in whole blood sample

    Changes from baseline for Potassium in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  34. Chloride in whole blood sample

    Changes from baseline for Chloride in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  35. Calcium in whole blood sample

    Changes from baseline for Calcium in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  36. Phosphate in whole blood sample

    Changes from baseline for Phosphate in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  37. Uric acid in whole blood sample

    Changes from baseline for Uric acid in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  38. Creatine kinase in whole blood sample

    Changes from baseline for Creatine kinase in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  39. Creatine kinase isoenzyme in whole blood sample

    Changes from baseline for Creatine kinase isoenzyme in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  40. Troponin-T (TnT) in whole blood sample

    Changes from baseline for Troponin-T in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  41. Troponin-I (TnI) in whole blood sample

    Changes from baseline for Troponin-I in whole blood

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  42. Urine protein in urine sample

    Changes from baseline for Urine protein in urine sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  43. Red blood cells in urine sample

    Changes from baseline for Red blood cells in urine sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  44. White blood cells in urine sample

    Changes from baseline for White blood cells in urine sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  45. PH in urine sample

    Changes from baseline for pH in urine sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  46. Ketone bodies in urine sample

    Changes from baseline for Ketone bodies in urine sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  47. Urine glucose in urine sample

    Changes from baseline for Urine glucose in urine sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  48. Urine bilirubin in urine sample

    Changes from baseline for Urine bilirubin in urine sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  49. Urine occult blood in urine sample

    Changes from baseline for Urine occult blood in urine sample

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  50. Heart Rate in beats per minute in beats per minute of ECG

    Changes from baseline for heart rate in beats per minute

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  51. RR Interval by ECG

    Changes from baseline for RR interval by ECG

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  52. PR Interval by ECG

    Changes from baseline for PR interval by ECG

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  53. QRS Interval by ECG

    Changes from baseline for QRS interval by ECG

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  54. QT Interval by ECG

    Changes from baseline for QT interval by ECG

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  55. QTcF by ECG

    Changes from baseline for QTcF interval by ECG

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  56. Left ventricular ejection fraction measured by Echocardiography

    Changes from baseline for Left ventricular ejection fraction measured by Echocardiography

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  57. Body (Ear) Temperature measurement in Vital Signs

    Changes from baseline for Body (Ear) Temperature

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  58. Pulse measurement in Vital Signs

    Changes from baseline for Pulse

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  59. Respiration Rate measurement in Vital Signs

    Changes from baseline for respiration rate in breaths of Vital Signs

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  60. Sitting Systolic Blood Pressure

    Changes from baseline for Sitting Systolic Blood Pressure

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  61. Sitting Diastolic Blood Pressure

    Changes from baseline for Sitting Diastolic Blood Pressure

    Time frame: Baseline, Day 1 of each 21-day cycle, and at the End of Treatment (EOT) visit (up to 1 year)

  62. The recommended Phase II dose

    Determine the Recommended Phase II Dose(mg/㎡) of HF158K1 and provide references for dose selection in future clinical studies.

    Time frame: After the end of the dose Expansion Phase(only Ic)

  63. Determine the maximum tolerated dose

    The dose at which the incidence of DLT was closest to the target probability of toxicity (30%).

    Time frame: The first administration of the investigational drug to the end of the first treatment cycle, lasting for 21 days.

Secondary outcomes

  1. HF158K1 pharmacokinetic parameters with Cmax

    Maximum plasma concentration (Cmax) after administration of HF158K1

    Time frame: Within 336 hours after the first and second administration

  2. AUC by plasma concentration of whole blood sample

    Area under plasma concentration -time curve after dose

    Time frame: Within 336 hours after the first and second administration

  3. Tmax by plasma concentration of whole blood sample

    Peak time (Tmax) after dose

    Time frame: Within 336 hours after the first and second administration

  4. T1/2 by plasma concentration of whole blood sample

    Elimination half-life (T1/2) after dose

    Time frame: Within 336 hours after the first and second administration

  5. CL by plasma concentration of whole blood sample

    Clearance (CL) after dose

    Time frame: Within 336 hours after the first and second administration

  6. Vd by plasma concentration of whole blood sample

    Volume of distribution(Vd) after dose

    Time frame: Within 336 hours after the first and second administration

  7. AUClast by plasma concentration of whole blood sample

    Ratios of geometric means of AUClast (Area under the plasma concentration-time curve from zero to time of last quantifiable concentration) after dose

    Time frame: Within 336 hours after the first and second administration

  8. The objective response rate(ORR) of HF158K1

    ORR is defined as the proportion of participants with complete response or partial response (CR+PR)

    Time frame: ORR will be calculated for all participants who have received the investigational drug at least once and have undergone at least one tumor evaluation after administration, assessed up to 51 weeks.

  9. disease control rate (DCR) of HF158K1

    DCR is defined as the proportion of participants with complete response stable disease and partial response (CR+PR+SD)

    Time frame: DCR will be calculated for all participants who have received the investigational drug at least once and have undergone at least one tumor evaluation after administration, assessed up to 51 weeks.

  10. duration of response(DOR) of HF158K1

    For duration of response (DOR), the Kaplan-Meier survival curve will be plotted to analyze their maximum, minimum, median and 95% confidence interval descriptively statistically.

    Time frame: DOR will be calculated for all participants who have received the investigational drug at least once and have undergone at least one tumor evaluation after administration, assessed up to 51 weeks.

  11. Analysis of immunogenicity

    Immunogenicity analyses related to anti-TL01 antibody will be performed based on IMS(Immunogenicity Analysis Set).

    Time frame: On the first day of the first cycle, on the first day of the fourth cycle, on the 21st day of the eighth cycle

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Jun 2027, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2023
First posted
May 17, 2023
StartActual
Dec 12, 2023
Primary completionEst.
Jun 23, 2027
CompletionEst.
Dec 23, 2027
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05861895
Lead sponsor
HighField Biopharmaceuticals Corporation
Responsible party
Sponsor
First posted
May 17, 2023
Start date
Dec 12, 2023
Primary completion
Jun 23, 2027 (estimated)
Completion
Dec 23, 2027 (estimated)
Last update
Jun 26, 2026

Study contacts

MINAL BARVE
principal investigator · Mary Crowley Cancer Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion